Revolutionizing MRI
Contrast Agents for Disease
Detection and Tracking
About Us
InLighta BioSciences L.L.C. was formed in 2012 by Dr. Jenny J. Yang, to develop patented protein-based contrast agents for pre-clinical and clinical imaging applications.
Our precision Magnetic Resonance Imaging (pMRI) technology addresses current deficiencies in medical diagnostics for early detection, monitoring disease progression, image-guided intervention, and evaluating drug delivery and therapeutic treatment.
Protein-based Contrast Agents (ProCA®s) combined with pMRI technologies, provide significantly improved sensitivity and accuracy for assessing a broad range of diseases including cancers and fibrosis, and effective molecular MR imaging of multiple biomarkers for liver, lung, breast, ovarian, and prostate cancers, and liver metastases from uveal melanoma, breast, and ovarian cancers.
Our Products/ Services
InLighta is currently developing high-contrast agents for MR imaging. The ProCA® series of contrast agents includes both blood pool agents and targeted contrast agents for specific biomarkers.
01
ProCA® Series
02
Blood Pool Agents
03
Targeted Contrast Agents
Targeted Biomarkers:
Collagen: Structural protein provides strength and elasticity to tissues
EGFR: Cell surface receptor regulating cell growth and division
HER2: Cell receptor in cell growth, linked to breast cancer.
PSMA: Overexpressed in prostate cancer, used for imaging and therapy.
Integrin: Cell adhesion receptors, crucial for cell attachment and signaling.
CXCR4: Chemokine receptor, guides cell migration, implicated in diseases..
CXCR12: Chemokine ligand regulating immune responses and migration.
GRPR: Found in gastrointestinal tissues, targeted in cancer imaging and treatment
Who We Are
Explore More
InLighta BioSciences IN THE NEWS
Our Sponsors / Investors
Our Valuable Resources
Conflict of interest policy
Get in Touch
"*" indicates required fields
Contact Information
Atlanta, GA 30303